Tempest Therapeutics developed HCC therapeutics, obtaining FDA and EMA designations and initiating pivotal trials in China.
2 reports, 1 independent
Updated Aug 12
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Tempest Therapeutics developed HCC therapeutics, obtaining FDA and EMA designations and initiating pivotal trials in China.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- Kazia Therapeutics Limited is seeking various regulatory designations from the FDA to support its drug development pipeline.
- Capricor Therapeutics is seeking regulatory approval from the FDA for clinical trials and has listed on the Nasdaq stock exchange, with a law firm based in New York City involved.
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.
- Decoy Therapeutics is listed on the Nasdaq stock exchange and is currently seeking expedited regulatory approval via FDA pathways.
- Both the FDA and the European Medicines Agency govern drug approval processes.
Coverage
Newest first; wire copies grouped- GlobeNewswireTempest Reports Second Quarter 2025 Financial Results and Provides Business Update Received clearance to proceed with pivotal trial of amezalpat combination therapy for first-line hepatocellular carc
- Unknown outlet